![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » UK Genetic Researchers Licence New Technologies
UK Genetic Researchers Licence New Technologies
Oxford Biomedica, a biotechnology spin-off company of the UK's Oxford University, has licensed its LentiVector gene delivery system to a large unnamed drug company. Although no financial terms of the deal were disclosed, the agreement envisages an annual maintenance fee as well as an up-front payment. According to Oxford Biomedica, LentiVector delivers genes to various cell types, or could potentially be developed as a stand-alone genetic therapy.
Last month, the company announced product agreements with US biotechnology firm Biogen Idec, and previous licensees also include US drug major Merck & Co. and UK drugmaker AstraZeneca.
Meanwhile, scientists at the University of Cambridge have licensed a new targeting technology for malignant tumours. Researchers said the system separates cancer stem cells from cell lines, allowing new therapies to target and destroy cancer-bearing stem cells without harming nonmalignant stem cells. The technology has been licensed to US company Stemline Therapeutics for undisclosed milestone payments and royalties.
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
18Jul
-
21Oct